NeuroScanner-Rare Diseases
CDSS RD (Rare Diseases) Neuro-Scanner is an enterprise-grade Clinical Decision Support System engineered to screen de-personalized Electronic Health Records (DEHR) and identify pediatric patients at high risk of rare genetic (orphan) disorders. Developed by iPavlov (an AI spin-off from MIPT) within the Smart Clinic Platform, the software bridges the critical gap in early diagnosis, transforming a multi-year diagnostic odyssey into immediate, targeted clinical action.
By synthesizing specialized Natural Language Processing (NLP), automated entity extraction, and deep neural representation models, Neuro-Scanner processes multi-structured medical histories, laboratory panels, and family pedigrees in milliseconds—enabling healthcare institutions to detect life-threatening genetic pathologies in children before irreversible clinical damage occurs.
Target Orphan Pathologies
The system is clinically validated and calibrated for high-precision screening of four major rare metabolic and storage disorders:
Mucopolysaccharidosis Type I (MPS I): Lysosomal storage disorder requiring early identification of multi-system clinical markers, bone deformities, and organomegaly.
Technical Architecture
Technology
Tech Platform
Technology Readiness Levels
Software Requirements Specifications Overview
The CDSS RD Neuro-Scanner is architected as a high-throughput, microservice-based decision support system designed to operate within air-gapped hospital intranet infrastructures and regional EMR data lakes.
Digital Transformation Domain
Project Type
Service Model
Business and Economic Impact
Industry
Project Status
Successfully Deployed in Industry
Economic Impact
Deploying AI-driven early screening for rare genetic disorders fundamentally alters healthcare economics by shifting clinical interventions from reactive, high-cost emergency management to proactive, targeted care.
Social & Environmental Impact
AI-powered electronic screening transforms public health by turning retrospective medical data into early life-saving clinical interventions.
Digital Transformation Domain
Unit Cost
$50,000
Pricing Model
Out-licensing & Milestone Payments
Standalone AI Software Product
MARKET CAPABILITY & CONSUMER GROUPS
TARGET MARKET SEGMENTS
KEY CLIENT & CUSTOMERS
PROJECTED SALES METRICS
Clinical Geneticists, Pediatricians, Chief Medical Officers (CMO), Heads of Regional Digital Healthcare, Medical IT System Administrators, Clinical Research Organizations (CROs), and Epidemiological Data Scientists.
Federal State Budgetary Institution «Almazov National Medical Research Centre» of the Ministry of Health of the Russian Federation; Sverdlovsk Region Ministry of Health; Regional Departments of Healthcare and Digital Health Transformation; Specialized Pediatric Clinical Hospitals; Research & Diagnostic Medical Centers.
• Phase 1 (Reference Clinical Centers): Initial deployment and clinical validation across 3–5 leading federal medical research institutions, including Almazov National Medical Research Centre and Burdenko Main Military Clinical Hospital.
• Phase 2 (Regional Healthcare Networks): System-wide rollout into regional Electronic Health Record (EHR/EMR) platforms across pilot territories, including the Sverdlovsk Region healthcare network.
• Phase 3 (National Scale-Up): Phased integration across regional outpatient networks, addressing the modernization pipeline of over 6,800+ polyclinics and diagnostic centers across 85 federal subjects under national digital healthcare programs.
• Phase 4 (Pharma & Research Consortia): Commercial out-licensing and specialized screening partnerships with multinational pharmaceutical enterprises (including orphan drug developers such as Sanofi) to accelerate early patient identification for targeted enzyme replacement therapies.
INVESTMENT RETURN & SUSTAINABILITY
PRODUCT SUPPORT COSTS
Initial Deployment & Support Cost: From 6 million RUB.
Average Annual Total Cost of Ownership (TCO): From 2 million RUB.
Final Pricing Specification: The exact costs will be finalized following the review and approval of the technical specifications (Statement of Work).
INVESTMENT RETURN
Neuro-Scanner provides immediate operational, clinical, and financial return on investment (ROI) across health system deployments.
Quantifiable ROI Metrics
Careers Anchor
Executive Roles
Project Biography
CDSS RD Neuro-Scanner was born at the intersection of fundamental neurocomputing and advanced digital healthcare. The project originated within iPavlov, an innovative AI spin-off founded out of the Moscow Institute of Physics and Technology (MIPT) as the commercial continuation of the National Technology Initiative (NTI) "Neurointelligence iPavlov" project with industrial backing from Sberbank.
My Companies
Career Trek
Career Recognition